Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

RedHill Biopharma (RDHL) Receivables - Other (2025)

RedHill Biopharma has reported Receivables - Other over the past 1 years, most recently at $3.1 million for Q4 2025.

  • Quarterly Receivables - Other changed N/A to $3.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $3.1 million for FY2025, N/A changed from the prior year.
  • Receivables - Other was $3.1 million for Q4 2025 at RedHill Biopharma.
  • Over five years, Receivables - Other peaked at $3.1 million in Q4 2025 and troughed at $3.1 million in Q4 2025.